Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Nikolaus B. Wagner, Andrea Forschner, Ulrike Leiter, et al.
British Journal of Cancer (2018) Vol. 119, Iss. 3, pp. 339-346
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Exploring immunotherapy in colorectal cancer
Junyong Weng, Shanbao Li, Zhonglin Zhu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 222
Tumour burden and efficacy of immune-checkpoint inhibitors
Filippo Gustavo Dall’Olio, Aurélien Marabelle, Caroline Caramella, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 75-90
Closed Access | Times Cited: 216
Lactate dehydrogenase: a marker of diminished antitumor immunity
Sandra van Wilpe, Rutger H.T. Koornstra, Martijn H. den Brok, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 147
Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
Tuba N. Gide, Inês Pires da Silva, Camelia Quek, et al.
OncoImmunology (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 79
The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
Biao Ning, Yixin Liu, Miao Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients
Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
Cancer (2023) Vol. 129, Iss. 11, pp. 1723-1734
Open Access | Times Cited: 35
Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy
Yongjuan Li, Xinyan Li, Jinmeng Yi, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 19
Closed Access | Times Cited: 34
A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
Linghong Huang, Xin‐Yuan Sun, Qinhua Zuo, et al.
Materials Today Bio (2025) Vol. 31, pp. 101523-101523
Open Access | Times Cited: 1
Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities
René G. Feichtinger, Roland Lang
Journal of Oncology (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 63
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
Martin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
European Journal of Cancer (2020) Vol. 138, pp. 125-132
Closed Access | Times Cited: 57
The Role of Calcium Signaling in Melanoma
Haoran Zhang, Zhe Chen, Aijun Zhang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1010-1010
Open Access | Times Cited: 31
Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
Rugilė Pikturnienė, Alvydas Česas, Sonata Jarmalaitė, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1197-1197
Open Access | Times Cited: 6
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
Yumi Kambayashi, Taku Fujimura, Takanori Hidaka, et al.
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 49
Novel Biomarkers for Personalized Cancer Immunotherapy
Yoshitaro Shindo, Shoichi Hazama, Ryouichi Tsunedomi, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1223-1223
Open Access | Times Cited: 44
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients
Kevin Prigent, Charline Lasnon, Emilien Ezine, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 8, pp. 2573-2585
Closed Access | Times Cited: 39
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
Fabio Valenti, Italia Falcone, Sara Ungania, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 3837-3837
Open Access | Times Cited: 38
Role of HMGB1 in Cutaneous Melanoma: State of the Art
Federica Li Pomi, Francesco Borgia, Paolo Custurone, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9327-9327
Open Access | Times Cited: 26
MnO2nanoparticles as a minimalist multimode vaccine adjuvant/delivery system to regulate antigen presenting cells for tumor immunotherapy
Ting Song, Yang Liao, Qinhua Zuo, et al.
Journal of Materials Chemistry B (2022) Vol. 10, Iss. 18, pp. 3474-3490
Closed Access | Times Cited: 23
Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
Jonathan N. Priantti, Maysa Vilbert, Thiago Madeira, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3754-3754
Open Access | Times Cited: 14
Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy
Jiacheng Lyu, Lin Bai, Yumiao Li, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma
Magali Boyer, Laure Cayrefourcq, O. Dereure, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 960-960
Open Access | Times Cited: 35
Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders
Fabrizio Michetti, Gabriele Di Sante, Maria Elisabetta Clementi, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 127, pp. 446-458
Closed Access | Times Cited: 31
Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies
Valeria Internò, Maria Chiara Sergi, Maria Elvira Metta, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1542-1542
Open Access | Times Cited: 12
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
Andrea Gaißler, Jonas Bochem, Janine Spreuer, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006802-e006802
Open Access | Times Cited: 11
Liquid biopsy for diagnostic and prognostic evaluation of melanoma
Nicholas Slusher, Nicholas Jones, T. NONAKA
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top